- Yale Digestive DiseasesTemple Medical Center40 Temple Street, Ste Suite 1ANew Haven, CT 06510
- Yale Digestive DiseasesYale Health Center55 Lock StreetNew Haven, CT 06511
- Yale Digestive DiseasesYale New Haven Hospital20 York StreetNew Haven, CT 06510
David N. Assis, MD
Biography
David N. Assis, MD, is a hepatologist who treats patients with liver and digestive diseases at Yale Liver Clinics and Yale New Haven Hospital. He primarily focuses on autoimmune liver diseases (autoimmune hepatitis, primary sclerosing cholangitis, and primary biliary cholangitis) and is co-director of the Yale Autoimmune and Cholestatic Liver Diseases Program. He also has a clinical focus on liver and digestive complications of cystic fibrosis. To provide comfort to his patients, Dr. Assis tells them: “We will always support you and walk closely with you throughout your medical journey, and provide the most cutting-edge discoveries to offer the best possible care.”
Dr. Assis became a hepatologist because he was fascinated by chronic liver diseases, and autoimmune liver diseases, in particular. An assistant professor of medicine (Digestive Diseases) at Yale School of Medicine (YSM), he dedicates his research to investigating the causes, mechanisms of disease, and novel treatments for these complex, rare disorders. In 2014, he was honored with YSM’s Kushlan Junior Faculty Award for his research work.
Dr. Assis is a member of the American Association for the Study of Liver Diseases and current Chair of the Special Interest Group for Cholestatic and Autoimmune Liver Diseases. He is also a member of the scientific and medical advisory committee of PSC Partners Seeking a Cure and the Autoimmune Hepatitis Association, and a member of the International PSC Study Group.
Dr. Assis is optimistic about developing better treatments for his patients. “There is much to be discovered in this field, and we are excited to bring about great progress within the next several years,” he says.
Titles
- Associate Professor of Medicine (Digestive Diseases)
- Director, Fellowship Program, Digestive Diseases
Education & Training
- FellowshipYale School of Medicine (2013)
- FellowshipYale School of Medicine (2012)
- Chief ResidencyThomas Jefferson University Hospital (2009)
- ResidencyThomas Jefferson University Hospital (2008)
- InternshipThomas Jefferson University, Hospital (2006)
- MDJefferson Medical College (2005)
- BSMessiah College (2001)
Languages Spoken
- English
- Português (Portuguese)
Additional Information
- Connecticut's Best Doctors 2019: Connecticut Magazine (2019)
- AB of Internal Medicine, Transpant Hepatology (2014, recertified: 2015)
- AB of Internal Medicine, Gastroenterology (2012)
- AB of Internal Medicine, Internal Medicine (2008, recertified: 2018)
- Hepatology (2013 - Present): Ad hoc reviewer.
- Kasper V, Assis D. Pathophysiology of Cystic Fibrosis Liver Disease. Pediatric Pulmonology 2024, 59: s98-s106. PMID: 39105342, DOI: 10.1002/ppul.26869.
- Gallucci G, Hayes C, Boyer J, Barbier O, Assis D, Ghonem N. PPAR-Mediated Bile Acid Glucuronidation: Therapeutic Targets for the Treatment of Cholestatic Liver Diseases. Cells 2024, 13: 1296. PMID: 39120326, PMCID: PMC11312002, DOI: 10.3390/cells13151296.
- Hussain N, Ma C, Hirschfield G, Walmsley M, Hanford P, Vesterhus M, Kowdley K, Bergquist A, Ponsioen C, Levy C, Assis D, Schramm C, Bowlus C, Trauner M, Aiyegbusi O, Jairath V, Trivedi P. Protocol for the development of a core outcome set for clinical trials in primary sclerosing cholangitis. BMJ Open 2024, 14: e080143. PMID: 38926149, PMCID: PMC11216047, DOI: 10.1136/bmjopen-2023-080143.
- Kochhar S, Assis D, Mack C, Izurieta H, Muratori L, Munoz A, Nordenberg D, Gidudu J, Blau E, Vierling J. Autoimmune hepatitis: Brighton Collaboration case definition and guidelines for data collection, analysis, and presentation of immunisation safety data. Vaccine 2024, 42: 1812-1825. PMID: 38368225, DOI: 10.1016/j.vaccine.2024.01.021.
- Yazdanfar M, Zepeda J, Dean R, Wu J, Levy C, Goldberg D, Lammert C, Prenner S, Reddy K, Pratt D, Forman L, Assis D, Lytvyak E, Montano-Loza A, Gordon S, Carey E, Ahn J, Schlansky B, Korzenik J, Karagozian R, Hameed B, Chandna S, Yu L, Bowlus C. African American race does not confer an increased risk of clinical events in patients with primary sclerosing cholangitis. Hepatology Communications 2024, 8 PMID: 38285883, PMCID: PMC10830082, DOI: 10.1097/hc9.0000000000000366.
- Sellers Z, Assis D, Paranjape S, Sathe M, Bodewes F, Bowen M, Cipolli M, Debray D, Green N, Hughan K, Hunt W, Leey J, Ling S, Morelli G, Peckham D, Pettit R, Philbrick A, Stoll J, Vavrina K, Allen S, Goodwin T, Hempstead S, Narkewicz M. Cystic fibrosis screening, evaluation, and management of hepatobiliary disease consensus recommendations. Hepatology 2023, 79: 1220-1238. PMID: 37934656, PMCID: PMC11020118, DOI: 10.1097/hep.0000000000000646.
- Zheng M, Hakim A, Konkwo C, Deaton A, Ward L, Genetics A, Silveira M, Assis D, Liapakis A, Jaffe A, Jiang Z, Curry M, Lai M, Cho M, Dykas D, Bale A, Mistry P, Vilarinho S. Advancing diagnosis and management of liver disease in adults through exome sequencing. EBioMedicine 2023, 95: 104747. PMID: 37566928, PMCID: PMC10433007, DOI: 10.1016/j.ebiom.2023.104747.
- Dean R, Yazdanfar M, Zepeda J, Levy C, Gordon S, Forman L, Lammert C, Assis D, Pratt D, Gungabissoon U, McGirr A, Mukherjee S, McLaughlin M, Bowlus C. WED-283 Investigating the cholestatic pruritus of primary sclerosing cholangitis (ItCh-PSC): a study of patients participating in the consortium for autoimmune liver disease (CALiD). Journal Of Hepatology 2023, 78: s388. DOI: 10.1016/s0168-8278(23)01040-1.
- Assis D, Bowlus C. Recent Advances in the Management of Primary Sclerosing Cholangitis. Clinical Gastroenterology And Hepatology 2023, 21: 2065-2075. PMID: 37084929, DOI: 10.1016/j.cgh.2023.04.004.
- Snijders R, Assis D, Oo Y, Sebode M, Taubert R, Willemse J, Tomsin B, Lohse A, Drenth J, Gevers T, Diseases T. Research gaps and opportunities in autoimmune hepatitis—Results of the international autoimmune hepatitis group research workshop 2022. Liver International 2023, 43: 1375-1384. PMID: 37035872, DOI: 10.1111/liv.15573.
- Bowlus C, Arrivé L, Bergquist A, Deneau M, Forman L, Ilyas S, Lunsford K, Martinez M, Sapisochin G, Shroff R, Tabibian J, Assis D. Reply: Insurance should cover vancomycin for primary sclerosing cholangitis. Hepatology 2023, 77: e176-e177. PMID: 36695291, DOI: 10.1097/hep.0000000000000305.
- Sayed A, Assis D, Silveira M, Deng Y, Ciarleglio M, Gaidos J, Proctor D, Al-Bawardy B. Outcomes of immunomodulator and advanced therapies for primary sclerosing cholangitis-associated inflammatory bowel disease. European Journal Of Gastroenterology & Hepatology 2023, 35: 270-274. PMID: 36708297, DOI: 10.1097/meg.0000000000002510.
- Forman L, Sapisochin G, Assis D, Arrivé L, Bergquist A, Bowlus C, Deneau M, Ilyas S, Lunsford K, Martinez M, Shroff R, Tabibian J. Reply: Living donor liver transplantation for people with PSC. Hepatology 2023, 77: e97-e98. PMID: 36732294, DOI: 10.1097/hep.0000000000000210.
- Vélez C, Freedman S, Assis D. Update in Advancing the Gastrointestinal Frontier in Cystic Fibrosis. Clinics In Chest Medicine 2022, 43: 743-755. PMID: 36344078, DOI: 10.1016/j.ccm.2022.07.001.
- Harrington C, Krishnan S, Mack CL, Cravedi P, Assis DN, Levitsky J. Noninvasive biomarkers for the diagnosis and management of autoimmune hepatitis. Hepatology 2022, 76: 1862-1879. PMID: 35611859, PMCID: PMC9796683, DOI: 10.1002/hep.32591.
- Bowlus CL, Arrivé L, Bergquist A, Deneau M, Forman L, Ilyas SI, Lunsford KE, Martinez M, Sapisochin G, Shroff R, Tabibian JH, Assis DN. AASLD practice guidance on primary sclerosing cholangitis and cholangiocarcinoma. Hepatology 2022, 77: 659-702. PMID: 36083140, DOI: 10.1002/hep.32771.
- Gallucci GM, Alsuwayt B, Auclair AM, Boyer JL, Assis DN, Ghonem NS. Fenofibrate Downregulates NF-κB Signaling to Inhibit Pro-inflammatory Cytokine Secretion in Human THP-1 Macrophages and During Primary Biliary Cholangitis. Inflammation 2022, 45: 2570-2581. PMID: 35838934, PMCID: PMC10853883, DOI: 10.1007/s10753-022-01713-1.
- Efe C, Lammert C, Taşçılar K, Dhanasekaran R, Ebik B, Higuera-de la Tijera F, Calışkan AR, Peralta M, Gerussi A, Massoumi H, Catana AM, Purnak T, Rigamonti C, Aldana AJG, Khakoo N, Nazal L, Frager S, Demir N, Irak K, Melekoğlu-Ellik Z, Kacmaz H, Balaban Y, Atay K, Eren F, Alvares-da-Silva MR, Cristoferi L, Urzua Á, Eşkazan T, Magro B, Snijders R, Barutçu S, Lytvyak E, Zazueta GM, Demirezer-Bolat A, Aydın M, Heurgue-Berlot A, De Martin E, Ekin N, Yıldırım S, Yavuz A, Bıyık M, Narro GC, Kıyıcı M, Akyıldız M, Kahramanoğlu-Aksoy E, Vincent M, Carr RM, Günşar F, Reyes EC, Harputluoğlu M, Aloman C, Gatselis NK, Üstündağ Y, Brahm J, Vargas NCE, Güzelbulut F, Garcia SR, Aguirre J, Anders M, Ratusnu N, Hatemi I, Mendizabal M, Floreani A, Fagiuoli S, Silva M, Idilman R, Satapathy SK, Silveira M, Drenth JPH, Dalekos GN, Assis DN, Björnsson E, Boyer JL, Yoshida EM, Invernizzi P, Levy C, Montano-Loza AJ, Schiano TD, Ridruejo E, Wahlin S. Effects of immunosuppressive drugs on COVID-19 severity in patients with autoimmune hepatitis. Liver International : Official Journal Of The International Association For The Study Of The Liver 2022, 42: 607-614. PMID: 34846800, DOI: 10.1111/liv.15121.
- Alrabadi LS, Dutton A, Rabiee A, Roberts SJ, Deng Y, Cusack L, Silveira MG, Ciarleglio M, Bucala R, Sinha R, Boyer JL, Assis DN. Mindfulness-based stress reduction may decrease stress, disease activity, and inflammatory cytokine levels in patients with autoimmune hepatitis. JHEP Reports 2022, 4: 100450. PMID: 35434588, PMCID: PMC9011026, DOI: 10.1016/j.jhepr.2022.100450.
- Sayed A, Silveira M, Assis D, Deng Y, Gaidos J, Proctor D, Al-Bawardy B. PREDICTORS AND OUTCOMES OF BIOLOGIC/IMMUNOSUPPRESSIVE THERAPY FOR PSC-ASSOCIATED IBD. Gastroenterology 2022, 162: s76. DOI: 10.1053/j.gastro.2021.12.161.
- Sayed A, Silveira M, Assis D, Deng Y, Gaidos J, Proctor D, Al-Bawardy B. PREDICTORS AND OUTCOMES OF BIOLOGIC/IMMUNOSUPPRESSIVE THERAPY FOR PSC-ASSOCIATED IBD. Inflammatory Bowel Diseases 2022, 28: s76-s76. DOI: 10.1093/ibd/izac015.124.
- Efe C, Dhanasekaran R, Lammert C, Ebik B, la Tijera F, Aloman C, Calışkan A, Peralta M, Gerussi A, Massoumi H, Catana AM, Torgutalp M, Purnak T, Rigamonti C, Aldana A, Khakoo N, Kacmaz H, Nazal L, Frager S, Demir N, Irak K, Ellik ZM, Balaban Y, Atay K, Eren F, Cristoferi L, Batıbay E, Urzua Á, Snijders R, Kıyıcı M, Akyıldız M, Ekin N, Carr RM, Harputluoğlu M, Hatemi I, Mendizabal M, Silva M, Idilman R, Silveira M, Drenth JPH, Assis DN, Björnsson E, Boyer JL, Invernizzi P, Levy C, Schiano TD, Ridruejo E, Wahlin S. Outcome of COVID‐19 in Patients With Autoimmune Hepatitis: An International Multicenter Study. Hepatology 2021, 73: 2099-2109. PMID: 33713486, PMCID: PMC8250536, DOI: 10.1002/hep.31797.
- Soroka CJ, Roberts SJ, Boyer JL, Assis DN. Role of Biliary Organoids in Cholestasis Research and Regenerative Medicine. Seminars In Liver Disease 2021, 41: 206-212. PMID: 33957696, DOI: 10.1055/s-0041-1728663.
- Guercio BJ, Iyer G, Kidwai WZ, Lacouture ME, Ghafoor S, Rossi AM, Assis DN, Chen YB, Busam KJ, Janjigian YY, Jhaveri K, Feldman DR, Capozzi A, Figueroa V, Bajorin DF, Rosenberg JE, Hollmann TJ, Funt SA. Treatment of Metastatic Extramammary Paget Disease with Combination Ipilimumab and Nivolumab: A Case Report. Case Reports In Oncology 2021, 14: 430-438. PMID: 33790764, PMCID: PMC7983595, DOI: 10.1159/000514345.
- Assis DN, Levy C. Oral Vancomycin or Ursodeoxycholic Acid for Pediatric Primary Sclerosing Cholangitis? The Uncontroversial Need for Randomized Controlled Trials. Hepatology 2021, 73: 887-889. PMID: 33403699, DOI: 10.1002/hep.31702.
- Kim HP, Lieber SR, Rogers ME, Moon AM, Loiselle M, Walker J, Assis DN, Safer R, Gomel R, Evon DM. A Systematic Review of Patient‐Reported Outcomes in Primary Biliary Cholangitis and Primary Sclerosing Cholangitis. Hepatology Communications 2020, 4: 1502-1515. PMID: 33024919, PMCID: PMC7527768, DOI: 10.1002/hep4.1567.
- Vierling JM, Kerkar N, Czaja AJ, Mack CL, Adams D, Assis D, Manns MP, Mayo MJ, Nayfeh T, Majzoub AMM, Alzuabi MA, Ding J, Haffar S, Murad MH, Alsawas M. Immunosuppressive Treatment Regimens in Autoimmune Hepatitis: Systematic Reviews and Meta‐Analyses Supporting American Association for the Study of Liver Diseases Guidelines. Hepatology 2020, 72: 753-769. PMID: 32500593, DOI: 10.1002/hep.31407.
- Soroka C, Roberts S, Hohenester S, Boyer J, Assis D. AS055 Co-culture of bile-derived organoids from primary sclerosing cholangitis patients with CD4+ T cells replicates pathogenic, CCL20 dependent biliary-immune interactions. Journal Of Hepatology 2020, 73: s41. DOI: 10.1016/s0168-8278(20)30634-6.
- Mack CL, Adams D, Assis DN, Kerkar N, Manns MP, Mayo MJ, Vierling JM, Alsawas M, Murad MH, Czaja AJ. Diagnosis and Management of Autoimmune Hepatitis in Adults and Children: 2019 Practice Guidance and Guidelines From the American Association for the Study of Liver Diseases. Hepatology 2020, 72: 671-722. PMID: 31863477, DOI: 10.1002/hep.31065.
- Ghonem NS, Auclair AM, Hemme CL, Gallucci GM, de la Rosa Rodriguez R, Boyer JL, Assis DN. Fenofibrate Improves Liver Function and Reduces the Toxicity of the Bile Acid Pool in Patients With Primary Biliary Cholangitis and Primary Sclerosing Cholangitis Who Are Partial Responders to Ursodiol. Clinical Pharmacology & Therapeutics 2020, 108: 1213-1223. PMID: 32480421, PMCID: PMC7886378, DOI: 10.1002/cpt.1930.
- Kim H, Lieber S, Rogers M, Moon A, Loiselle M, Walker J, Assis D, Evon D. Su1652 COMPREHENSIVE REVIEW OF PATIENT-REPORTED OUTCOME CONCEPTS AND INSTRUMENTS IN THE PBC AND PSC SCIENTIFIC LITERATURE. Gastroenterology 2020, 158: s-1375. DOI: 10.1016/s0016-5085(20)34105-6.
- Assis DN. Immunopathogenesis of Autoimmune Hepatitis. Clinical Liver Disease 2020, 15: 129-132. PMID: 32257125, PMCID: PMC7128031, DOI: 10.1002/cld.873.
- Shung DL, Assis DN. Machine Learning in a Complex Disease: PREsTo Improves the Prognostication of Primary Sclerosing Cholangitis. Hepatology 2020, 71: 8-10. PMID: 31850533, DOI: 10.1002/hep.31069.
- Soroka CJ, Assis DN, Alrabadi LS, Roberts S, Cusack L, Jaffe AB, Boyer JL. Bile‐Derived Organoids From Patients With Primary Sclerosing Cholangitis Recapitulate Their Inflammatory Immune Profile. Hepatology 2019, 70: 871-882. PMID: 30561836, DOI: 10.1002/hep.30470.
- Taylor SA, Assis DN, Mack CL. The Contribution of B Cells in Autoimmune Liver Diseases. Seminars In Liver Disease 2019, 39: 422-431. PMID: 31226726, PMCID: PMC6800599, DOI: 10.1055/s-0039-1688751.
- Lynch KD, Chapman RW, Keshav S, Montano-Loza AJ, Mason AL, Kremer AE, Vetter M, de Krijger M, Ponsioen CY, Trivedi P, Hirschfield G, Schramm C, Liu CH, Bowlus CL, Estes DJ, Pratt D, Hedin C, Bergquist A, de Vries AC, van der Woude CJ, Yu L, Assis DN, Boyer J, Ytting H, Hallibasic E, Trauner M, Marschall HU, Daretti LM, Marzioni M, Yimam KK, Perin N, Floreani A, Beretta-Piccoli BT, Rogers JK, Group I, Levy C. Effects of Vedolizumab in Patients With Primary Sclerosing Cholangitis and Inflammatory Bowel Diseases. Clinical Gastroenterology And Hepatology 2019, 18: 179-187.e6. PMID: 31100458, PMCID: PMC6941216, DOI: 10.1016/j.cgh.2019.05.013.
- Soroka CJ, Assis DN, Boyer JL. Patient-Derived Organoids from Human Bile: An In Vitro Method to Study Cholangiopathies. Methods In Molecular Biology 2019, 1981: 363-372. PMID: 31016667, DOI: 10.1007/978-1-4939-9420-5_24.
- Hakim A, Zhang X, DeLisle A, Oral EA, Dykas D, Drzewiecki K, Assis DN, Silveira M, Batisti J, Jain D, Bale A, Mistry PK, Vilarinho S. Clinical utility of genomic analysis in adults with idiopathic liver disease. Journal Of Hepatology 2019, 70: 1214-1221. PMID: 31000363, PMCID: PMC6526061, DOI: 10.1016/j.jhep.2019.01.036.
- The Immunopathogenesis of Autoimmune HepatitisClinical Liver Disease (in press)
- Gurung A, Assis DN, McCarty TR, Mitchell KA, Boyer JL, Jain D. Histologic features of autoimmune hepatitis: a critical appraisal. Human Pathology 2018, 82: 51-60. PMID: 30041025, DOI: 10.1016/j.humpath.2018.07.014.
- Assis DN. Chronic Complications of Cholestasis Evaluation and Management. Clinics In Liver Disease 2018, 22: 533-544. PMID: 30259851, DOI: 10.1016/j.cld.2018.03.014.
- Bowlus C, Assis D, Goldberg D. 43 Primary and Secondary Sclerosing Cholangitis. 2018, 626-647.e6. DOI: 10.1016/b978-0-323-37591-7.00043-4.
- Chapter 43: Primary and Secondary Sclerosing CholangitisBowlus CL, Assis DN, Goldberg DS. Zakim and Boyer’s Hepatology: A Textbook of Liver Disease. Elsevier (7th Edition).
- Goldberg DS, Levy C, Yimam K, Gordon SC, Forman L, Verna E, Yu L, Rahimi R, Schwarz K, Eksteen B, Pratt D, Boyer JL, Assis D, Bowlus C. Primary Sclerosing Cholangitis Is Not Rare Among Blacks in a Multicenter North American Consortium. Clinical Gastroenterology And Hepatology 2017, 16: 591-593. PMID: 29102704, PMCID: PMC5860952, DOI: 10.1016/j.cgh.2017.10.028.
- Assis DN, Debray D. Gallbladder and bile duct disease in Cystic Fibrosis. Journal Of Cystic Fibrosis 2017, 16: s62-s69. PMID: 28986023, DOI: 10.1016/j.jcf.2017.07.006.
- Goldberg D, Yimam K, Eksteen B, Levy C, Pratt D, Schwarz K, Forman L, Yu L, Rahimi R, Assis D, Bowlus C. Mo1444 Prevalence of Primary Sclerosing Cholangitis in Black Patients: Results of a Multi-Center North American Consortium. Gastroenterology 2017, 152: s1185. DOI: 10.1016/s0016-5085(17)33954-9.
- Assis DN, Abdelghany O, Cai SY, Gossard AA, Eaton JE, Keach JC, Deng Y, Setchell KD, Ciarleglio M, Lindor KD, Boyer JL. Combination Therapy of All-Trans Retinoic Acid With Ursodeoxycholic Acid in Patients With Primary Sclerosing Cholangitis. Journal Of Clinical Gastroenterology 2017, 51: e11-e16. PMID: 27428727, PMCID: PMC5218875, DOI: 10.1097/mcg.0000000000000591.
- Roberts S, Leng L, Soroka C, Boyer J, Bucala R, Assis D. FRI-393 Macrophage migration inhibitory factor (MIF) modulates T-cell proliferation and hepatic inflammation in a model of autoimmune liver disease. Journal Of Hepatology 2017, 66: s363-s364. DOI: 10.1016/s0168-8278(17)31067-x.
- Assis DN, Takahashi H, Leng L, Zeniya M, Boyer JL, Bucala R. A Macrophage Migration Inhibitory Factor Polymorphism Is Associated with Autoimmune Hepatitis Severity in US and Japanese Patients. Digestive Diseases And Sciences 2016, 61: 3506-3512. PMID: 27696094, PMCID: PMC5106299, DOI: 10.1007/s10620-016-4322-z.
- Kim BS, Stoppe C, Grieb G, Leng L, Sauler M, Assis D, Simons D, Boecker AH, Schulte W, Piecychna M, Hager S, Bernhagen J, Pallua N, Bucala R. The clinical significance of the MIF homolog d-dopachrome tautomerase (MIF-2) and its circulating receptor (sCD74) in burn. Burns 2016, 42: 1265-1276. PMID: 27209369, PMCID: PMC5010466, DOI: 10.1016/j.burns.2016.02.005.
- Tandon P, Ripoll C, Assis D, Wongcharatrawee S, Groszmann RJ, Garcia-Tsao G. The interpretation of hepatic venous pressure gradient tracings – excellent interobserver agreement unrelated to experience. Liver International 2016, 36: 1160-1166. PMID: 26763558, DOI: 10.1111/liv.13065.
- Assis DN, Freedman SD. Gastrointestinal Disorders in Cystic Fibrosis. Clinics In Chest Medicine 2015, 37: 109-118. PMID: 26857772, DOI: 10.1016/j.ccm.2015.11.004.
- Ghonem NS, Assis DN, Boyer JL. Fibrates and cholestasis. Hepatology 2015, 62: 635-643. PMID: 25678132, PMCID: PMC4515188, DOI: 10.1002/hep.27744.
- Assis DN, Levy C. Editorial: environmental risk factors for PSC with and without IBD – the story unfolds. Alimentary Pharmacology & Therapeutics 2015, 41: 1214-1216. PMID: 25939466, DOI: 10.1111/apt.13186.
- Assis DN, Leng L, Du X, Zhang CK, Grieb G, Merk M, Garcia AB, McCrann C, Chapiro J, Meinhardt A, Mizue Y, Nikolic‐Paterson D, Bernhagen J, Kaplan MM, Zhao H, Boyer JL, Bucala R. The role of macrophage migration inhibitory factor in autoimmune liver disease. Hepatology 2013, 59: 580-591. PMID: 23913513, PMCID: PMC3877200, DOI: 10.1002/hep.26664.
- Plotkin E, Assis D, Boyer J. Now you see it, now you don't. Hepatology 2013, 58: 446-447. DOI: 10.1002/hep.26439.
- Now you see it, now you don’t.Plotkin E, Assis DN, Boyer JL. Hepatology. 2013;58:446-447 (Case Report)
- Assis DN, Lim JK. New Pharmacotherapy for Hepatitis C. Clinical Pharmacology & Therapeutics 2012, 92: 294-305. PMID: 22850602, DOI: 10.1038/clpt.2012.103.
- Assis DN, Pollak J, Schilsky ML, Emre S. Successful Treatment of a Bleeding Umbilical Varix by Percutaneous Umbilical Vein Embolization With Sclerotherapy. Journal Of Clinical Gastroenterology 2012, 46: 115-118. PMID: 21897280, DOI: 10.1097/mcg.0b013e31822b7f9a.
- Cimsit B, Assis D, Caldwell C, Arvelakis A, Taddei T, Kulkarni S, Schilsky M, Emre S. Successful Treatment of Fibrosing Cholestatic Hepatitis After Liver Transplantation. Transplantation Proceedings 2011, 43: 905-908. PMID: 21486625, DOI: 10.1016/j.transproceed.2011.02.034.
- Assis DN, Schilsky ML. Testing and management of thrombocytopenia and coagulopathy in the pre- and postliver transplant patient. Minerva Gastroenterology 2010, 56: 331-43. PMID: 21037549.
- Assis DN, Navarro VJ. Human drug hepatotoxicity: a contemporary clinical perspective. Expert Opinion On Drug Metabolism & Toxicology 2009, 5: 463-73. PMID: 19416083, DOI: 10.1517/17425250902927386.
- Verma SK, Mitchell DG, Bergin D, Lakhman Y, Austin A, Verma M, Assis D, Herrine SK, Parker L. Dilated cisternae chyli: a sign of uncompensated cirrhosis at MR imaging. Abdominal Imaging 2009, 34: 211-6. PMID: 18219518, DOI: 10.1007/s00261-008-9369-7.
- Kowalski T, Nathwani RA, Assis D, Salese L, Banwait K, Loren D. Post-sphincterotomy transampullary balloon dilation is a safe and effective technique. Digestive Diseases And Sciences 2009, 54: 670-4. PMID: 18594970, DOI: 10.1007/s10620-008-0376-x.
- Rossi S, Assis DN, Awsare M, Brunner M, Skole K, Rai J, Andrel J, Herrine SK, Reddy RK, Navarro VJ. Use of over-the-counter analgesics in patients with chronic liver disease: physicians' recommendations. Drug Safety 2008, 31: 261-70. PMID: 18302450, DOI: 10.2165/00002018-200831030-00007.
- Mylin LM, Schell TD, Epler M, Kusuma C, Assis D, Matsko C, Smith A, Allebach A, Tevethia SS. Diversity of escape variant mutations in Simian virus 40 large tumor antigen (SV40 Tag) epitopes selected by cytotoxic T lymphocyte (CTL) clones. Virology 2007, 364: 155-68. PMID: 17368499, PMCID: PMC3866617, DOI: 10.1016/j.virol.2007.02.007.
- Yale Digestive DiseasesTemple Medical Center40 Temple Street, Ste Suite 1ANew Haven, CT 06510
- Yale Digestive DiseasesYale Health Center55 Lock StreetNew Haven, CT 06511
- Yale Digestive DiseasesYale New Haven Hospital20 York StreetNew Haven, CT 06510
Biography
David N. Assis, MD, is a hepatologist who treats patients with liver and digestive diseases at Yale Liver Clinics and Yale New Haven Hospital. He primarily focuses on autoimmune liver diseases (autoimmune hepatitis, primary sclerosing cholangitis, and primary biliary cholangitis) and is co-director of the Yale Autoimmune and Cholestatic Liver Diseases Program. He also has a clinical focus on liver and digestive complications of cystic fibrosis. To provide comfort to his patients, Dr. Assis tells them: “We will always support you and walk closely with you throughout your medical journey, and provide the most cutting-edge discoveries to offer the best possible care.”
Dr. Assis became a hepatologist because he was fascinated by chronic liver diseases, and autoimmune liver diseases, in particular. An assistant professor of medicine (Digestive Diseases) at Yale School of Medicine (YSM), he dedicates his research to investigating the causes, mechanisms of disease, and novel treatments for these complex, rare disorders. In 2014, he was honored with YSM’s Kushlan Junior Faculty Award for his research work.
Dr. Assis is a member of the American Association for the Study of Liver Diseases and current Chair of the Special Interest Group for Cholestatic and Autoimmune Liver Diseases. He is also a member of the scientific and medical advisory committee of PSC Partners Seeking a Cure and the Autoimmune Hepatitis Association, and a member of the International PSC Study Group.
Dr. Assis is optimistic about developing better treatments for his patients. “There is much to be discovered in this field, and we are excited to bring about great progress within the next several years,” he says.
Titles
- Associate Professor of Medicine (Digestive Diseases)
- Director, Fellowship Program, Digestive Diseases
Education & Training
- FellowshipYale School of Medicine (2013)
- FellowshipYale School of Medicine (2012)
- Chief ResidencyThomas Jefferson University Hospital (2009)
- ResidencyThomas Jefferson University Hospital (2008)
- InternshipThomas Jefferson University, Hospital (2006)
- MDJefferson Medical College (2005)
- BSMessiah College (2001)
Languages Spoken
- English
- Português (Portuguese)
Additional Information
- Connecticut's Best Doctors 2019: Connecticut Magazine (2019)
- AB of Internal Medicine, Transpant Hepatology (2014, recertified: 2015)
- AB of Internal Medicine, Gastroenterology (2012)
- AB of Internal Medicine, Internal Medicine (2008, recertified: 2018)
- Hepatology (2013 - Present): Ad hoc reviewer.
- Kasper V, Assis D. Pathophysiology of Cystic Fibrosis Liver Disease. Pediatric Pulmonology 2024, 59: s98-s106. PMID: 39105342, DOI: 10.1002/ppul.26869.
- Gallucci G, Hayes C, Boyer J, Barbier O, Assis D, Ghonem N. PPAR-Mediated Bile Acid Glucuronidation: Therapeutic Targets for the Treatment of Cholestatic Liver Diseases. Cells 2024, 13: 1296. PMID: 39120326, PMCID: PMC11312002, DOI: 10.3390/cells13151296.
- Hussain N, Ma C, Hirschfield G, Walmsley M, Hanford P, Vesterhus M, Kowdley K, Bergquist A, Ponsioen C, Levy C, Assis D, Schramm C, Bowlus C, Trauner M, Aiyegbusi O, Jairath V, Trivedi P. Protocol for the development of a core outcome set for clinical trials in primary sclerosing cholangitis. BMJ Open 2024, 14: e080143. PMID: 38926149, PMCID: PMC11216047, DOI: 10.1136/bmjopen-2023-080143.
- Kochhar S, Assis D, Mack C, Izurieta H, Muratori L, Munoz A, Nordenberg D, Gidudu J, Blau E, Vierling J. Autoimmune hepatitis: Brighton Collaboration case definition and guidelines for data collection, analysis, and presentation of immunisation safety data. Vaccine 2024, 42: 1812-1825. PMID: 38368225, DOI: 10.1016/j.vaccine.2024.01.021.
- Yazdanfar M, Zepeda J, Dean R, Wu J, Levy C, Goldberg D, Lammert C, Prenner S, Reddy K, Pratt D, Forman L, Assis D, Lytvyak E, Montano-Loza A, Gordon S, Carey E, Ahn J, Schlansky B, Korzenik J, Karagozian R, Hameed B, Chandna S, Yu L, Bowlus C. African American race does not confer an increased risk of clinical events in patients with primary sclerosing cholangitis. Hepatology Communications 2024, 8 PMID: 38285883, PMCID: PMC10830082, DOI: 10.1097/hc9.0000000000000366.
- Sellers Z, Assis D, Paranjape S, Sathe M, Bodewes F, Bowen M, Cipolli M, Debray D, Green N, Hughan K, Hunt W, Leey J, Ling S, Morelli G, Peckham D, Pettit R, Philbrick A, Stoll J, Vavrina K, Allen S, Goodwin T, Hempstead S, Narkewicz M. Cystic fibrosis screening, evaluation, and management of hepatobiliary disease consensus recommendations. Hepatology 2023, 79: 1220-1238. PMID: 37934656, PMCID: PMC11020118, DOI: 10.1097/hep.0000000000000646.
- Zheng M, Hakim A, Konkwo C, Deaton A, Ward L, Genetics A, Silveira M, Assis D, Liapakis A, Jaffe A, Jiang Z, Curry M, Lai M, Cho M, Dykas D, Bale A, Mistry P, Vilarinho S. Advancing diagnosis and management of liver disease in adults through exome sequencing. EBioMedicine 2023, 95: 104747. PMID: 37566928, PMCID: PMC10433007, DOI: 10.1016/j.ebiom.2023.104747.
- Dean R, Yazdanfar M, Zepeda J, Levy C, Gordon S, Forman L, Lammert C, Assis D, Pratt D, Gungabissoon U, McGirr A, Mukherjee S, McLaughlin M, Bowlus C. WED-283 Investigating the cholestatic pruritus of primary sclerosing cholangitis (ItCh-PSC): a study of patients participating in the consortium for autoimmune liver disease (CALiD). Journal Of Hepatology 2023, 78: s388. DOI: 10.1016/s0168-8278(23)01040-1.
- Assis D, Bowlus C. Recent Advances in the Management of Primary Sclerosing Cholangitis. Clinical Gastroenterology And Hepatology 2023, 21: 2065-2075. PMID: 37084929, DOI: 10.1016/j.cgh.2023.04.004.
- Snijders R, Assis D, Oo Y, Sebode M, Taubert R, Willemse J, Tomsin B, Lohse A, Drenth J, Gevers T, Diseases T. Research gaps and opportunities in autoimmune hepatitis—Results of the international autoimmune hepatitis group research workshop 2022. Liver International 2023, 43: 1375-1384. PMID: 37035872, DOI: 10.1111/liv.15573.
- Bowlus C, Arrivé L, Bergquist A, Deneau M, Forman L, Ilyas S, Lunsford K, Martinez M, Sapisochin G, Shroff R, Tabibian J, Assis D. Reply: Insurance should cover vancomycin for primary sclerosing cholangitis. Hepatology 2023, 77: e176-e177. PMID: 36695291, DOI: 10.1097/hep.0000000000000305.
- Sayed A, Assis D, Silveira M, Deng Y, Ciarleglio M, Gaidos J, Proctor D, Al-Bawardy B. Outcomes of immunomodulator and advanced therapies for primary sclerosing cholangitis-associated inflammatory bowel disease. European Journal Of Gastroenterology & Hepatology 2023, 35: 270-274. PMID: 36708297, DOI: 10.1097/meg.0000000000002510.
- Forman L, Sapisochin G, Assis D, Arrivé L, Bergquist A, Bowlus C, Deneau M, Ilyas S, Lunsford K, Martinez M, Shroff R, Tabibian J. Reply: Living donor liver transplantation for people with PSC. Hepatology 2023, 77: e97-e98. PMID: 36732294, DOI: 10.1097/hep.0000000000000210.
- Vélez C, Freedman S, Assis D. Update in Advancing the Gastrointestinal Frontier in Cystic Fibrosis. Clinics In Chest Medicine 2022, 43: 743-755. PMID: 36344078, DOI: 10.1016/j.ccm.2022.07.001.
- Harrington C, Krishnan S, Mack CL, Cravedi P, Assis DN, Levitsky J. Noninvasive biomarkers for the diagnosis and management of autoimmune hepatitis. Hepatology 2022, 76: 1862-1879. PMID: 35611859, PMCID: PMC9796683, DOI: 10.1002/hep.32591.
- Bowlus CL, Arrivé L, Bergquist A, Deneau M, Forman L, Ilyas SI, Lunsford KE, Martinez M, Sapisochin G, Shroff R, Tabibian JH, Assis DN. AASLD practice guidance on primary sclerosing cholangitis and cholangiocarcinoma. Hepatology 2022, 77: 659-702. PMID: 36083140, DOI: 10.1002/hep.32771.
- Gallucci GM, Alsuwayt B, Auclair AM, Boyer JL, Assis DN, Ghonem NS. Fenofibrate Downregulates NF-κB Signaling to Inhibit Pro-inflammatory Cytokine Secretion in Human THP-1 Macrophages and During Primary Biliary Cholangitis. Inflammation 2022, 45: 2570-2581. PMID: 35838934, PMCID: PMC10853883, DOI: 10.1007/s10753-022-01713-1.
- Efe C, Lammert C, Taşçılar K, Dhanasekaran R, Ebik B, Higuera-de la Tijera F, Calışkan AR, Peralta M, Gerussi A, Massoumi H, Catana AM, Purnak T, Rigamonti C, Aldana AJG, Khakoo N, Nazal L, Frager S, Demir N, Irak K, Melekoğlu-Ellik Z, Kacmaz H, Balaban Y, Atay K, Eren F, Alvares-da-Silva MR, Cristoferi L, Urzua Á, Eşkazan T, Magro B, Snijders R, Barutçu S, Lytvyak E, Zazueta GM, Demirezer-Bolat A, Aydın M, Heurgue-Berlot A, De Martin E, Ekin N, Yıldırım S, Yavuz A, Bıyık M, Narro GC, Kıyıcı M, Akyıldız M, Kahramanoğlu-Aksoy E, Vincent M, Carr RM, Günşar F, Reyes EC, Harputluoğlu M, Aloman C, Gatselis NK, Üstündağ Y, Brahm J, Vargas NCE, Güzelbulut F, Garcia SR, Aguirre J, Anders M, Ratusnu N, Hatemi I, Mendizabal M, Floreani A, Fagiuoli S, Silva M, Idilman R, Satapathy SK, Silveira M, Drenth JPH, Dalekos GN, Assis DN, Björnsson E, Boyer JL, Yoshida EM, Invernizzi P, Levy C, Montano-Loza AJ, Schiano TD, Ridruejo E, Wahlin S. Effects of immunosuppressive drugs on COVID-19 severity in patients with autoimmune hepatitis. Liver International : Official Journal Of The International Association For The Study Of The Liver 2022, 42: 607-614. PMID: 34846800, DOI: 10.1111/liv.15121.
- Alrabadi LS, Dutton A, Rabiee A, Roberts SJ, Deng Y, Cusack L, Silveira MG, Ciarleglio M, Bucala R, Sinha R, Boyer JL, Assis DN. Mindfulness-based stress reduction may decrease stress, disease activity, and inflammatory cytokine levels in patients with autoimmune hepatitis. JHEP Reports 2022, 4: 100450. PMID: 35434588, PMCID: PMC9011026, DOI: 10.1016/j.jhepr.2022.100450.
- Sayed A, Silveira M, Assis D, Deng Y, Gaidos J, Proctor D, Al-Bawardy B. PREDICTORS AND OUTCOMES OF BIOLOGIC/IMMUNOSUPPRESSIVE THERAPY FOR PSC-ASSOCIATED IBD. Gastroenterology 2022, 162: s76. DOI: 10.1053/j.gastro.2021.12.161.
- Sayed A, Silveira M, Assis D, Deng Y, Gaidos J, Proctor D, Al-Bawardy B. PREDICTORS AND OUTCOMES OF BIOLOGIC/IMMUNOSUPPRESSIVE THERAPY FOR PSC-ASSOCIATED IBD. Inflammatory Bowel Diseases 2022, 28: s76-s76. DOI: 10.1093/ibd/izac015.124.
- Efe C, Dhanasekaran R, Lammert C, Ebik B, la Tijera F, Aloman C, Calışkan A, Peralta M, Gerussi A, Massoumi H, Catana AM, Torgutalp M, Purnak T, Rigamonti C, Aldana A, Khakoo N, Kacmaz H, Nazal L, Frager S, Demir N, Irak K, Ellik ZM, Balaban Y, Atay K, Eren F, Cristoferi L, Batıbay E, Urzua Á, Snijders R, Kıyıcı M, Akyıldız M, Ekin N, Carr RM, Harputluoğlu M, Hatemi I, Mendizabal M, Silva M, Idilman R, Silveira M, Drenth JPH, Assis DN, Björnsson E, Boyer JL, Invernizzi P, Levy C, Schiano TD, Ridruejo E, Wahlin S. Outcome of COVID‐19 in Patients With Autoimmune Hepatitis: An International Multicenter Study. Hepatology 2021, 73: 2099-2109. PMID: 33713486, PMCID: PMC8250536, DOI: 10.1002/hep.31797.
- Soroka CJ, Roberts SJ, Boyer JL, Assis DN. Role of Biliary Organoids in Cholestasis Research and Regenerative Medicine. Seminars In Liver Disease 2021, 41: 206-212. PMID: 33957696, DOI: 10.1055/s-0041-1728663.
- Guercio BJ, Iyer G, Kidwai WZ, Lacouture ME, Ghafoor S, Rossi AM, Assis DN, Chen YB, Busam KJ, Janjigian YY, Jhaveri K, Feldman DR, Capozzi A, Figueroa V, Bajorin DF, Rosenberg JE, Hollmann TJ, Funt SA. Treatment of Metastatic Extramammary Paget Disease with Combination Ipilimumab and Nivolumab: A Case Report. Case Reports In Oncology 2021, 14: 430-438. PMID: 33790764, PMCID: PMC7983595, DOI: 10.1159/000514345.
- Assis DN, Levy C. Oral Vancomycin or Ursodeoxycholic Acid for Pediatric Primary Sclerosing Cholangitis? The Uncontroversial Need for Randomized Controlled Trials. Hepatology 2021, 73: 887-889. PMID: 33403699, DOI: 10.1002/hep.31702.
- Kim HP, Lieber SR, Rogers ME, Moon AM, Loiselle M, Walker J, Assis DN, Safer R, Gomel R, Evon DM. A Systematic Review of Patient‐Reported Outcomes in Primary Biliary Cholangitis and Primary Sclerosing Cholangitis. Hepatology Communications 2020, 4: 1502-1515. PMID: 33024919, PMCID: PMC7527768, DOI: 10.1002/hep4.1567.
- Vierling JM, Kerkar N, Czaja AJ, Mack CL, Adams D, Assis D, Manns MP, Mayo MJ, Nayfeh T, Majzoub AMM, Alzuabi MA, Ding J, Haffar S, Murad MH, Alsawas M. Immunosuppressive Treatment Regimens in Autoimmune Hepatitis: Systematic Reviews and Meta‐Analyses Supporting American Association for the Study of Liver Diseases Guidelines. Hepatology 2020, 72: 753-769. PMID: 32500593, DOI: 10.1002/hep.31407.
- Soroka C, Roberts S, Hohenester S, Boyer J, Assis D. AS055 Co-culture of bile-derived organoids from primary sclerosing cholangitis patients with CD4+ T cells replicates pathogenic, CCL20 dependent biliary-immune interactions. Journal Of Hepatology 2020, 73: s41. DOI: 10.1016/s0168-8278(20)30634-6.
- Mack CL, Adams D, Assis DN, Kerkar N, Manns MP, Mayo MJ, Vierling JM, Alsawas M, Murad MH, Czaja AJ. Diagnosis and Management of Autoimmune Hepatitis in Adults and Children: 2019 Practice Guidance and Guidelines From the American Association for the Study of Liver Diseases. Hepatology 2020, 72: 671-722. PMID: 31863477, DOI: 10.1002/hep.31065.
- Ghonem NS, Auclair AM, Hemme CL, Gallucci GM, de la Rosa Rodriguez R, Boyer JL, Assis DN. Fenofibrate Improves Liver Function and Reduces the Toxicity of the Bile Acid Pool in Patients With Primary Biliary Cholangitis and Primary Sclerosing Cholangitis Who Are Partial Responders to Ursodiol. Clinical Pharmacology & Therapeutics 2020, 108: 1213-1223. PMID: 32480421, PMCID: PMC7886378, DOI: 10.1002/cpt.1930.
- Kim H, Lieber S, Rogers M, Moon A, Loiselle M, Walker J, Assis D, Evon D. Su1652 COMPREHENSIVE REVIEW OF PATIENT-REPORTED OUTCOME CONCEPTS AND INSTRUMENTS IN THE PBC AND PSC SCIENTIFIC LITERATURE. Gastroenterology 2020, 158: s-1375. DOI: 10.1016/s0016-5085(20)34105-6.
- Assis DN. Immunopathogenesis of Autoimmune Hepatitis. Clinical Liver Disease 2020, 15: 129-132. PMID: 32257125, PMCID: PMC7128031, DOI: 10.1002/cld.873.
- Shung DL, Assis DN. Machine Learning in a Complex Disease: PREsTo Improves the Prognostication of Primary Sclerosing Cholangitis. Hepatology 2020, 71: 8-10. PMID: 31850533, DOI: 10.1002/hep.31069.
- Soroka CJ, Assis DN, Alrabadi LS, Roberts S, Cusack L, Jaffe AB, Boyer JL. Bile‐Derived Organoids From Patients With Primary Sclerosing Cholangitis Recapitulate Their Inflammatory Immune Profile. Hepatology 2019, 70: 871-882. PMID: 30561836, DOI: 10.1002/hep.30470.
- Taylor SA, Assis DN, Mack CL. The Contribution of B Cells in Autoimmune Liver Diseases. Seminars In Liver Disease 2019, 39: 422-431. PMID: 31226726, PMCID: PMC6800599, DOI: 10.1055/s-0039-1688751.
- Lynch KD, Chapman RW, Keshav S, Montano-Loza AJ, Mason AL, Kremer AE, Vetter M, de Krijger M, Ponsioen CY, Trivedi P, Hirschfield G, Schramm C, Liu CH, Bowlus CL, Estes DJ, Pratt D, Hedin C, Bergquist A, de Vries AC, van der Woude CJ, Yu L, Assis DN, Boyer J, Ytting H, Hallibasic E, Trauner M, Marschall HU, Daretti LM, Marzioni M, Yimam KK, Perin N, Floreani A, Beretta-Piccoli BT, Rogers JK, Group I, Levy C. Effects of Vedolizumab in Patients With Primary Sclerosing Cholangitis and Inflammatory Bowel Diseases. Clinical Gastroenterology And Hepatology 2019, 18: 179-187.e6. PMID: 31100458, PMCID: PMC6941216, DOI: 10.1016/j.cgh.2019.05.013.
- Soroka CJ, Assis DN, Boyer JL. Patient-Derived Organoids from Human Bile: An In Vitro Method to Study Cholangiopathies. Methods In Molecular Biology 2019, 1981: 363-372. PMID: 31016667, DOI: 10.1007/978-1-4939-9420-5_24.
- Hakim A, Zhang X, DeLisle A, Oral EA, Dykas D, Drzewiecki K, Assis DN, Silveira M, Batisti J, Jain D, Bale A, Mistry PK, Vilarinho S. Clinical utility of genomic analysis in adults with idiopathic liver disease. Journal Of Hepatology 2019, 70: 1214-1221. PMID: 31000363, PMCID: PMC6526061, DOI: 10.1016/j.jhep.2019.01.036.
- The Immunopathogenesis of Autoimmune HepatitisClinical Liver Disease (in press)
- Gurung A, Assis DN, McCarty TR, Mitchell KA, Boyer JL, Jain D. Histologic features of autoimmune hepatitis: a critical appraisal. Human Pathology 2018, 82: 51-60. PMID: 30041025, DOI: 10.1016/j.humpath.2018.07.014.
- Assis DN. Chronic Complications of Cholestasis Evaluation and Management. Clinics In Liver Disease 2018, 22: 533-544. PMID: 30259851, DOI: 10.1016/j.cld.2018.03.014.
- Bowlus C, Assis D, Goldberg D. 43 Primary and Secondary Sclerosing Cholangitis. 2018, 626-647.e6. DOI: 10.1016/b978-0-323-37591-7.00043-4.
- Chapter 43: Primary and Secondary Sclerosing CholangitisBowlus CL, Assis DN, Goldberg DS. Zakim and Boyer’s Hepatology: A Textbook of Liver Disease. Elsevier (7th Edition).
- Goldberg DS, Levy C, Yimam K, Gordon SC, Forman L, Verna E, Yu L, Rahimi R, Schwarz K, Eksteen B, Pratt D, Boyer JL, Assis D, Bowlus C. Primary Sclerosing Cholangitis Is Not Rare Among Blacks in a Multicenter North American Consortium. Clinical Gastroenterology And Hepatology 2017, 16: 591-593. PMID: 29102704, PMCID: PMC5860952, DOI: 10.1016/j.cgh.2017.10.028.
- Assis DN, Debray D. Gallbladder and bile duct disease in Cystic Fibrosis. Journal Of Cystic Fibrosis 2017, 16: s62-s69. PMID: 28986023, DOI: 10.1016/j.jcf.2017.07.006.
- Goldberg D, Yimam K, Eksteen B, Levy C, Pratt D, Schwarz K, Forman L, Yu L, Rahimi R, Assis D, Bowlus C. Mo1444 Prevalence of Primary Sclerosing Cholangitis in Black Patients: Results of a Multi-Center North American Consortium. Gastroenterology 2017, 152: s1185. DOI: 10.1016/s0016-5085(17)33954-9.
- Assis DN, Abdelghany O, Cai SY, Gossard AA, Eaton JE, Keach JC, Deng Y, Setchell KD, Ciarleglio M, Lindor KD, Boyer JL. Combination Therapy of All-Trans Retinoic Acid With Ursodeoxycholic Acid in Patients With Primary Sclerosing Cholangitis. Journal Of Clinical Gastroenterology 2017, 51: e11-e16. PMID: 27428727, PMCID: PMC5218875, DOI: 10.1097/mcg.0000000000000591.
- Roberts S, Leng L, Soroka C, Boyer J, Bucala R, Assis D. FRI-393 Macrophage migration inhibitory factor (MIF) modulates T-cell proliferation and hepatic inflammation in a model of autoimmune liver disease. Journal Of Hepatology 2017, 66: s363-s364. DOI: 10.1016/s0168-8278(17)31067-x.
- Assis DN, Takahashi H, Leng L, Zeniya M, Boyer JL, Bucala R. A Macrophage Migration Inhibitory Factor Polymorphism Is Associated with Autoimmune Hepatitis Severity in US and Japanese Patients. Digestive Diseases And Sciences 2016, 61: 3506-3512. PMID: 27696094, PMCID: PMC5106299, DOI: 10.1007/s10620-016-4322-z.
- Kim BS, Stoppe C, Grieb G, Leng L, Sauler M, Assis D, Simons D, Boecker AH, Schulte W, Piecychna M, Hager S, Bernhagen J, Pallua N, Bucala R. The clinical significance of the MIF homolog d-dopachrome tautomerase (MIF-2) and its circulating receptor (sCD74) in burn. Burns 2016, 42: 1265-1276. PMID: 27209369, PMCID: PMC5010466, DOI: 10.1016/j.burns.2016.02.005.
- Tandon P, Ripoll C, Assis D, Wongcharatrawee S, Groszmann RJ, Garcia-Tsao G. The interpretation of hepatic venous pressure gradient tracings – excellent interobserver agreement unrelated to experience. Liver International 2016, 36: 1160-1166. PMID: 26763558, DOI: 10.1111/liv.13065.
- Assis DN, Freedman SD. Gastrointestinal Disorders in Cystic Fibrosis. Clinics In Chest Medicine 2015, 37: 109-118. PMID: 26857772, DOI: 10.1016/j.ccm.2015.11.004.
- Ghonem NS, Assis DN, Boyer JL. Fibrates and cholestasis. Hepatology 2015, 62: 635-643. PMID: 25678132, PMCID: PMC4515188, DOI: 10.1002/hep.27744.
- Assis DN, Levy C. Editorial: environmental risk factors for PSC with and without IBD – the story unfolds. Alimentary Pharmacology & Therapeutics 2015, 41: 1214-1216. PMID: 25939466, DOI: 10.1111/apt.13186.
- Assis DN, Leng L, Du X, Zhang CK, Grieb G, Merk M, Garcia AB, McCrann C, Chapiro J, Meinhardt A, Mizue Y, Nikolic‐Paterson D, Bernhagen J, Kaplan MM, Zhao H, Boyer JL, Bucala R. The role of macrophage migration inhibitory factor in autoimmune liver disease. Hepatology 2013, 59: 580-591. PMID: 23913513, PMCID: PMC3877200, DOI: 10.1002/hep.26664.
- Plotkin E, Assis D, Boyer J. Now you see it, now you don't. Hepatology 2013, 58: 446-447. DOI: 10.1002/hep.26439.
- Now you see it, now you don’t.Plotkin E, Assis DN, Boyer JL. Hepatology. 2013;58:446-447 (Case Report)
- Assis DN, Lim JK. New Pharmacotherapy for Hepatitis C. Clinical Pharmacology & Therapeutics 2012, 92: 294-305. PMID: 22850602, DOI: 10.1038/clpt.2012.103.
- Assis DN, Pollak J, Schilsky ML, Emre S. Successful Treatment of a Bleeding Umbilical Varix by Percutaneous Umbilical Vein Embolization With Sclerotherapy. Journal Of Clinical Gastroenterology 2012, 46: 115-118. PMID: 21897280, DOI: 10.1097/mcg.0b013e31822b7f9a.
- Cimsit B, Assis D, Caldwell C, Arvelakis A, Taddei T, Kulkarni S, Schilsky M, Emre S. Successful Treatment of Fibrosing Cholestatic Hepatitis After Liver Transplantation. Transplantation Proceedings 2011, 43: 905-908. PMID: 21486625, DOI: 10.1016/j.transproceed.2011.02.034.
- Assis DN, Schilsky ML. Testing and management of thrombocytopenia and coagulopathy in the pre- and postliver transplant patient. Minerva Gastroenterology 2010, 56: 331-43. PMID: 21037549.
- Assis DN, Navarro VJ. Human drug hepatotoxicity: a contemporary clinical perspective. Expert Opinion On Drug Metabolism & Toxicology 2009, 5: 463-73. PMID: 19416083, DOI: 10.1517/17425250902927386.
- Verma SK, Mitchell DG, Bergin D, Lakhman Y, Austin A, Verma M, Assis D, Herrine SK, Parker L. Dilated cisternae chyli: a sign of uncompensated cirrhosis at MR imaging. Abdominal Imaging 2009, 34: 211-6. PMID: 18219518, DOI: 10.1007/s00261-008-9369-7.
- Kowalski T, Nathwani RA, Assis D, Salese L, Banwait K, Loren D. Post-sphincterotomy transampullary balloon dilation is a safe and effective technique. Digestive Diseases And Sciences 2009, 54: 670-4. PMID: 18594970, DOI: 10.1007/s10620-008-0376-x.
- Rossi S, Assis DN, Awsare M, Brunner M, Skole K, Rai J, Andrel J, Herrine SK, Reddy RK, Navarro VJ. Use of over-the-counter analgesics in patients with chronic liver disease: physicians' recommendations. Drug Safety 2008, 31: 261-70. PMID: 18302450, DOI: 10.2165/00002018-200831030-00007.
- Mylin LM, Schell TD, Epler M, Kusuma C, Assis D, Matsko C, Smith A, Allebach A, Tevethia SS. Diversity of escape variant mutations in Simian virus 40 large tumor antigen (SV40 Tag) epitopes selected by cytotoxic T lymphocyte (CTL) clones. Virology 2007, 364: 155-68. PMID: 17368499, PMCID: PMC3866617, DOI: 10.1016/j.virol.2007.02.007.
- Yale Digestive DiseasesTemple Medical Center40 Temple Street, Ste Suite 1ANew Haven, CT 06510
- Yale Digestive DiseasesYale Health Center55 Lock StreetNew Haven, CT 06511
- Yale Digestive DiseasesYale New Haven Hospital20 York StreetNew Haven, CT 06510
- Yale Digestive DiseasesTemple Medical Center40 Temple Street, Ste Suite 1ANew Haven, CT 06510
- Yale Digestive DiseasesYale Health Center55 Lock StreetNew Haven, CT 06511
- Yale Digestive DiseasesYale New Haven Hospital20 York StreetNew Haven, CT 06510